Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 284

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 2
Chunk 284
---
    2025
    (Successor)  
    (Pro
    forma, Predecessor and Successor)  
    Difference 

    Net cash used in operating activities 
    $(9,068,702) 
    $(8,617,285) 
    $(451,417)
  
    Net cash provided by
    financing activities: 
     9,044,316  
     9,748,916  
     (704,600)
  
    Net
    (decrease) increase in cash, restricted cash and cash equivalents 
    $(24,386) 
    $1,131,631  
    $(1,156,017)

Net
cash used in operating activities

Net cash used in operating
activities for the six months ended June 30, 2025 primarily reflected a net loss of $10,523,000, adjusted for the reconciliation of non-cash
items such as depreciation expense of $146,000, stock-based compensation of $488,000, stock-based inducement expense of $864,000, and
amortization of right-of-use asset of $391,000, and changes in operating asset and liabilities primarily consisting of an increase in
prepaid expenses and other current assets of $169,000, an increase in accounts payable of $562,000, a decrease in accrued liabilities
of $404,000, and a decrease in operating lease liabilities of $423,000.

Net cash used in operating activities for the six months ended June
30, 2024 primarily reflected a net loss of $4,748,000, adjusted for the reconciliation of non-cash items such as a gain of settlement
of liabilities with vendors of $589,000, depreciation expense of $228,000, stock-based compensation of $1,489,000, amortization of right-of-use
asset of $353,000 and a gain on revaluation of earnout liability and the preferred stock warrant liability of $5,020,000, and changes
in operating asset and liabilities primarily consisting of an increase in prepaid expenses and other current assets of $269,000, a decrease
in accounts payable of $551,000, an increase in accrued liabilities of $941,000, and a decrease in operating lease liabilities of $450,000.

Net
cash provided by financing activities

Net cash provided by financing
activities for the six months ended June 30, 2025 amounted to $9,